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MARKET SEGMENTATION AND THE IMPACT OF ONLINE MEDIA. 
 
 
Introduction. 
 
The impact of online media has and will continue to generate a great deal of interest 
across many businesses, yet most pharmaceutical companies struggle with the concept.1 
Patients and caregivers have become more active in their pursuit for health information. 2 
Studies have shown that over 85% now use the internet as their primary source of data. 3 
The website “PatientsLikeMe” is an example of how individuals with life changing illnesses 
share their experiences with others. It reports to have over 72,000 members in its 
community. Their primary goal is to give patients an insight to their future, highlighting the 
prognosis and likely quality of life expectancies. 4 
 
It is not just the patients and their caregivers who are using these online portals for first-
hand information. A study by Google5 identified 86% of physicians use the internet for 
medical research: more importantly, 77% focus specifically on drug data and 31% have 
changed a patient’s medication following the review. The study also identified that the 
majority use search engines to find material: drilling into the top three results only. This 
means that pharmaceutical companies have to optimise and update their websites with the 
appropriate keywords if they hope to utilise online media as a source to generate new 
business. 
 
The growth of medical websites has been phenomenal although it is difficult to 
substantiate the statement.  In an attempt to validate it, this paper carried out a simple 
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exercise looking at some basic medical search terms using Google in January 2011. The 
objective was to identify how many likely pages were available for the users to review. The 
results are illustrated in table 1: 
 
Search Term Approximate results 
Medical symptoms 15,200,000 
Medical Advice 28,600,000 
Medical Therapies 8,230,000 
Table 1: Google search results count. 
 
The exercise also looked at users’ online search habits: it identified that there were just 
over 45 million monthly searches for the terms related to medical symptoms, advice and 
therapies (this study was done using Google’s keyword analyser). Based on the current 
internet evolution statistics, one can conclude that it is only likely to grow. Online media 
cannot and should not be ignored by pharmaceutical companies. Unfortunately, very few 
pharmaceutical company websites appear on page one of Google when users search for 
terms relating to medical symptoms, advice or therapies.  
 
Figures for 2008 indicate that there were over 1.5 billion internet users6 which is roughly 
26% of the world population. The 10 year growth of internet users was over 750%.6 It is 
not just computers driving the expansion; the sales of smartphones, which also provides a 
channel to access online media, grew by 96% in the 3rd quarter last year.7 They now 
occupy just under 20% of the mobile phone market. 
 
Online media has removed geographical barriers; it can create numerous opportunities for 
a medical marketing team to increase its brand awareness across the world. These brands 
will provide pharmaceutical companies with the opportunity to connect with its 
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customers;8,9 both healthcare professionals and patients. Brand management should not 
be limited to just the product portfolio, they must include all services and the corporate 
image. There is a concern however, Giles10 identified that marketers within the industry 
have a poor understanding of the concept of branding. Businesses need to re-evaluate 
their marketing structure and look to the internet as a means of obtaining new 
opportunities.  
 
Before embarking on such a venture, pharmaceutical companies must first decide exactly 
who its customers are and how it deals with them. Patients and caregiver are the ultimate 
consumers but regulatory restrictions make it difficult for direct communications.11 Is this 
likely to change? Should this situation be challenged? 
 
Pharmaceutical Companies’ Customers. 
When it comes to prescription only medicines (POMs), most people think that 
pharmaceutical companies deal directly with healthcare professionals (HCPs):  physicians, 
pharmacists, nurses etc. They in turn manage the patients and caregivers (see figure 1): 
 
Figure 1: Old interaction between pharmaceutical companies, HCPs and patients. 
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This belief is largely due to the legislative constratints that drive the industry’s code of 
practice. As it has already been mentioned, the advent of social media has meant that 
patients and caregivers have become more empowered and are demanding more from the 
sector. It means that pharmaceutical companies need to move to an integrated 
communications model (see figure 2): 
 
Figure 2: New interaction between pharmaceutical companies, HCPs and patients. 
 
In doing so, they must not alienate HCPs or infringe regulatory protocol. Regrettably the 
model painted above does not give the full picture. In reality pharmaceutical companies 
have a much more complicated customer base. The classic definition of a customer is: 
 
A person who buys goods or services from a shop or business. 
Oxford English Dictionary12 
 
Such a definition does not serve the pharmaceutical market and this paper would like to 
propose changing the definition to: 
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Customers of pharmaceutical companies are made up of a series of stakeholders. 
Each group of stakeholders provide access or authority to the next level of 
stakeholders to either; list, buy, prescribe, use or consume the products (or 
services). 
 
In essence, the market is very different to that of the normal B2B or B2C industries. Here 
the market is made up of stakeholders who act as gatekeepers, guarding the access to the 
next stage. A product has to go through a number of gatekeepers before it can be finally 
consumed or used. These gatekeepers have very specific requirements that need 
satisfying before the business can move to the next level. The process is made more 
complicated by the fact that different counties have very different rules and regulations 
relating to how a product can be introduced. Figure 3 illustrates the flow of the customer 
chain with examples of who the stakeholders are: 
 
Figure 3 : A typical pharmaceutical company’s customer chain. 
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The author has learnt from experience that many pharmaceutical companies have already 
segmented the first three sets of stakeholders. Each tends to be managed by separate 
teams but little consideration is made to the variability within these segments. More 
alarmingly, the fourth stakeholder group of consumers is seldom considered at all. Yet it 
potentially provides one of the biggest opportunities for the business. Clearly the question 
of segmentation strategies should be considered as part of the executive agenda.  
 
Segmentation Strategies. 
Segmentation is essentially a classification exercise, where individuals are believed to be 
related in certain ways.13 It allows organisations to develop strategies which maximise their 
product’s potential.14 When developing such strategies, businesses should see the market 
being composed of many different divisions.15 Marketers should design their products and 
services to target specific segments and although Dibb16 argues that there are many 
different interpretations of this theory, the underlying principle is that it targets a selection 
of customers in order to provide a specific promotional message. 
 
Kotler17 suggests that segmentation, targeting and positioning are all interlinked: 
segmentation centres on the variables within a market; targeting is about deciding how 
many segments should be targeted; positioning places the products or services in the 
mind of the customer by communicating the desired benefit. Kotler also suggested that a 
business could either: 
 
 Concentrate on a single segment with one product and marketing mix. 
 Offer one product and marketing mix to a number of different segments. 
 Produce different products and marketing mixes for each segment. 
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Unfortunately these ideas are not wholly true for the medical sector. This paper has 
already highlighted the fact that the classic definitions of a market and its customers are 
not relevant: there are many stakeholders that need satisfying before the market can be 
unlocked.  As such, the segmentation model which was first developed by Smith18 needs 
to be adapted specifically for pharmaceutical companies.  
 
A review of the customer chain has identified that the number of stakeholders increases 
substantially as it gets closer to the final consumer (see figure 4). This means that a single 
approach to segmentation across the whole chain is likely to lead to the wrong 
conclusions. This paper proposes that the segmentation exercise should be done in two 
stages: 
 
1. The first stage focuses on the market access phase. (ie, the regulatory bodies, 
strategic buying authorities and insurance companies). 
2. The second stage focuses on market development. (ie, the healthcare 
professionals, patients and caregivers). 
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Figure 4 : Number of individuals involved in the customer chain. 
 
Stage One: Market Access  
The first stage is all about filling a need: it identifies the commercial viability for launching a 
new product or creating a new service. The stakeholders involved require a holistic view of 
the product and its proposed use. The numbers involved in this group are small, which 
means that the marketing and sales process can be tailored to suit each individual’s need. 
These individual plans tend to focus on: 
  
 Therapy. 
 Geographic. 
 Demographic. 
 Psychographic. 
 Behaviouristic. 
 
The concept is best demonstrated with an example (note, this example is purely 
illustrative): 
 
A pharmaceutical company is looking to launch a new drug in England. The drug is 
to be taken orally once a day to treat paediatric epilepsy. 
 
Therapy is an oral anti-epileptic drug. 
 
Geography is England, so the target stakeholders will be the National Institute for 
Health and Clinical Excellence (NICE) and then the 10 strategic health authorities 
located in England (once approval has been given by NICE). 
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Demographics apply to children with epilepsy, so an analysis of the prevalence of 
this condition is required to support the business case. 
 
Psychographics is based on the fact that neurologist and parents prefer 
administering an oral treatment as opposed to any evasive surgery (note, there are 
no studies to back this point, it is only being used as an illustration). 
 
Behaviouristic relates to the health economics of the product and how it can 
benefit the quality of life for the patient. 
  
So, even though the plans were developed to suit individual needs there are clearly 
elements of the classic segmentation process included in the final analysis.  The marketing 
or commercial teams involved need to understand the importance of this factor. 
 
Stage Two: Market Development 
The second stage relates to the market development phase. Here, the stakeholders will 
either; prescribe, use, administer or consume the products. These individuals will be the 
HCPs, patients or caregivers and the numbers involved could now be in the millions. This 
means that the expectations and needs are likely to vary significantly. A single marketing 
message will not satisfy the total market requirement: further segmentation must take 
place with the appropriate marketing strategies incorporated. Unfortunately, it has been 
the author’s experience that too many businesses still focus on developing a single 
message for the HCP group.  This hypothesis is reinforced by Jenkins and McDonald19 
who identified that managers tend to segment their markets not on customer groupings but 
on internal products.  
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Segmentation is a skill and should be classed as a science, backed up with evidence. This 
means that marketers will have to master a new range of technical competences. For 
those who are already embracing it, there should be no issues. For those who have not, 
they face a painful journey along the path of change.20 Indeed, Levitt21 had already 
identified that there are many businesses that are unwilling to recognise change for fear 
that it will undermine their entire strategy. Levitt’s21 study focused on the general business 
environment, so does his theory replicate itself when considering pharmaceutical 
companies? The question goes beyond the brief of this paper, but further research would 
be interesting. Needless to say, for success to be achieved, the issues related to change 
management must be addressed. 
 
Today’s economic climate brings with it many caveats, least of which are the pressures on 
time and resource. To date, there is no agreement on any formal way of carrying out 
segmentation: it is highly unlike that such a generic procedure would work for this sector 
anyway. In fact, there have been many academics who have argued against adopting a 
formal segmentation processes,22 but equally, there have been even more who advocate 
the use of complex systems.23 
 
Clearly some form of segmentation must take place. The solution must be simple and 
effective if it is to be adopted by practitioners. Cluster analysis could be the answer: many 
market researches already used it as a means of classification.13 It is an inductive 
technique and the empirical rules it uses can easily be amended and developed to suit any 
needs. 

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The technique proposed is an adapted version of divisive clustering.24 It is one that the 
author has already employed with great success. All customers are initially treated as a 
single large cluster, they are then divided into smaller and smaller clusters. The premise is 
centered on the buying (or usage) behaviours because such a factor is easily obtained by 
companies. The method is as follows (see also table 2 for an example): 
 
1. Focus on HCPs data only (it is generally much easier to obtain). 
2. Obtain the sales (usage) figures by customers for a given period (annual figures 
would be best). 
3. Sort the data into descending order, then for each customer calculate the 
cumulative sales. 
4. Establish the percentage that each cumulative value is of the total sales. 
5. Split the data into three clusters (this is the process of dividing into smaller groups): 
 
 Percentage of cumulative sales less than or equal to 25%. 
 Percentage of cumulative sales greater 25% but less than or equal to75%. 
 Percentage of cumulative sales greater 75%. 
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Table 2: An example of the clustering method. 
 
Four distinct clusters are created (the principles are similar to that used in the Pareto 
analysis25) which the author has called: 
 
 Advocates. 
 Users. 
 Testers. 
 Newbies: this group is not in the sales (usage) figures as they are potential 
customers who are not currently buying or using the product yet. 
 
Advocates are the top prescribers, the number of stakeholders involved in this group 
is small, which means that the marketing and sales process can be tailored to suit the 
individual’s need. They will account for approximately 1% to 5% of the customer base. 
These HCPs are ideal candidates to help promote the product amongst their peers. 
 
Users account for the bulk of the business: their numbers range from between 10% to 
15% of the customer base. The plan should be to convert users into advocates. 
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Testers account for approximately 75% of the customer base. This segment tends to 
be the long tail of the portfolio and it provides the business with the greatest opportunity 
for gaining extra market share. 
 
Newbies are those individuals not doing any business with the organisation, hence 
they do not appear on the sales list. They may be unaware of the product(s) or 
service(s) provided by the pharmaceutical company or have chosen to ignore them.  
The business needs to introduce strategies to entice these individuals to use the 
brands.  
 
Due to privacy laws, the information relating to patients and their product usage will be 
difficult to obtain. Expensive market research programmes are needed to establish the 
clusters. The author has been fortunate enough to have carried out a number of these 
reviews covering different disease groups. In all, it can be concluded that the profiles are 
very similar to that identified in the HCP group.  The advocates tend to be the chronic 
sufferers. The users are those with the classic symptoms who comply well with their 
medical regimen. The testers tend to be those individuals who have either classic or mild 
symptoms but have poor compliance. Finally the newbies are a mixture of the chronic, 
classical and mild suffers but are all on different medications (if at all any). 
 
Having identified all these different groups of customers what should a business now be 
doing? Each cluster has very different needs so tactical plans must be developed to satisfy 
them. The best way to do that is to review the marketing mix. 
 
Segmentation and the Marketing Mix. 
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It can be argued that the marketing mix acts as the foundation for setting all marketing 
plans. Many businesses focus solely on the four Ps: Price, Promotion, Place and Product. 
It was Borden26 who expanded the concept to include; Process, Physical Evidence and 
People. On further inspection it has become clear that this extended mix is more relevant 
for pharmaceutical companies than any others. It is this mix that needs to be considered 
when trying to manage the various segments identified above.  
 
The best way to analyse the factors is to consider each of the marketing mix elements 
individually whilst comparing it to the various segments: 
 
Product: The product familiarisation is critical when dealing with the HCPs. 
Sampling and demonstrations are the best way to increase awareness. Online 
media is also a good way of spreading the word and there are a number of tactical 
strategies that can be put in place including email marketing, webinars (web 
seminars), video and audio podcasts. Due to legislative restrictions, pharmaceutical 
companies cannot target patients and caregivers directly with product information 
(POM products). They have to use utilise the concept of medical education and 
promote the corporate brand instead. 
  
Promotion: PR, advertising and promotion is all about generating the right 
message; it should focus on the customer’s needs.  An element of research is 
required for this process. Sinha28 supports the idea that businesses should utilise 
the key rule of “pull marketing”: allowing the customer to discover the product or 
service themselves instead of having it constantly pushed in front of them. With 
over 45 million searches done every month on words and phrases related to 
medical symptoms, the internet must be the ideal place to focus the promotion plan.  
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Bearing in mind that the “testers” and “Newbies” account for over 80% of the 
market, could such a tactic generate more business? No studies are available for 
the pharmaceutical sector but there is a lot of evidence to support in the wider 
commercial field. 27 
 
Once again the rules of marketing need to change, as this paper has already 
mentioned, legislation restricts manufacturers advertising directly to patients and 
caregivers. Many pharmaceutical companies still adopt the safe route and focus 
only on HCPs. Regrettably, if businesses want to dominate the results of internet 
searches, they need to mobilise the bulk of the users: these happen to be the 
patients and caregivers. E-strategies need to be developed with external link 
building programmes27 and it is the patients and caregivers who they should target. 
To avoid falling foul of the regulations, businesses should focus on medical 
education as a means to capture the imagination of these consumers: if they like it 
they will share it in the electronic community. In turn it will increase the equity of the 
web page and move it up the Google ranking (be warned this is not an overnight 
fix). 
  
Price: The product price will depend on the sector and geographical region. As an 
example, patients in the USA are more sensitive to price than patients in the UK. 
This is due to the fact that US citizens have to pay indirectly through their health 
insurance systems whereas UK citizens will have it reimbursed through the National 
Health system. Price is also often used as a tool to entice new customers or 
maintain the business: this could mean that the marketing mix is out of sync and the 
brand equity is being eroded. 
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Place / distribution: There are a number of channels open to pharmaceutical 
companies and they include: 
 
 Hospital channels. 
 Community channels 
 Pharmacy Channels. 
 Home Delivery channels. 
 Internet channels. 
 
With the exception of the first stakeholder group (regulator bodies), all the other 
segments are likely to be interested in this characteristic. In reality it creates 
additional sub-segments and sub-clusters. The skilled marketer should see this as 
an opportunity to add value. 
 
Process: These are the systems used by the pharmaceutical company to support 
the management and delivery of the products and services. More and more of the 
stakeholders are demanding a better flow of information. There are now extranets 
that provide secure details about pricing, rebates, deliveries and much more. This 
element can be a real differentiator: it could be a reason why a company could lose 
or gain business.  
 
The process will impact all segments and clusters: the easier it is the more likely 
customers will stay and do business. 
 
Physical evidence: In the medical industry, physical evidence is paramount. It is 
the first and third group of stakeholders (regulatory bodies and HCPs) that focus on 
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this factor, although as already mentioned, patients and caregivers have begun to 
review product efficacy. HCPs rely on detail documentation of clinical trials but the 
consumers look to forums and social networks for their information. Marketers need 
to start reviewing how their brands are being perceived over the internet.  
 
Advocates and users are likely to be less concerned about the physical evidence 
whereas testers and newbies will need more reassurance. 
  
People: The people aspect is critical in the selling process. The second and third 
stakeholder groups (strategic buying authorities and HCPs) are where 
pharmaceutical companies should concentrate their efforts. Relationship building in 
medical sales can be the factor that wins the order.29 The link to the patient and 
caregiver is very much at an “arms distance”: the use of traditional and electronic 
communications tools are the mechanisms used to include this segment. 
 
Advocates and users require careful management: customer retention must remain 
a top priority for any business. The sales team will need to work on building the 
relationship in the tester and newbie segments: a focus on trust and support is key 
to building the business. 
 
It should be very clear to the reader that segmentation within the medical sector is very 
different to that of the general industry. To be successful pharmaceutical companies must 
adapt and apply their strategic and tactical plans to each group. They must also start to 
consider how to incorporate the internet into these plans. 
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Conclusion and Further Research. 
Segmentation is all about positioning brands and targeting customers using a various 
marketing mixes. Promotion is a key element of the marketing mix and the internet is the 
ideal means for disseminating specific messages. Patients and caregivers play an 
important part in optimising search engine results because of the numbers involved. 
Pharmaceutical marketers need to start including medical education strategies on the web 
when promoting their brands because online media has already had a major impact in 
sectors outside of the medical industry. It is highly likely that success will be seen by those 
medical companies that embracing this channel. 
 
The segmentation process reviewed was based on products that had already been 
developed. It looked at the interaction between the customers providing the licence for 
use, those that listed it on their buying portfolios, those that prescribed it and finally those 
that ultimately consumed it.  No attempt was made to look at segmentation “pre-product 
development”. Would there be any different processes or types of segmentation? The 
author suggests that it is highly likely and that companies would have different means to 
manage the area. Some could be classed as “market orientated organizations”,30  involving 
customers at every stage. The others would be those who were “product orientated 
organization”31 where R&D make all the decisions. Either way, it is unclear what part 
marketing would play in the process and how the markets would be segmented. Further 
research should be carried out to look at this particular dilemma. 
 
The paper identified that the segmentation process was a means for businesses to 
position and target their brands with different marketing mixes. It also identified that the 
internet has a big part to play in getting the message to the patients and their caregivers. 
These messages should be restricted to medical education. Direct referencing of products 
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is not allowed so it is the corporate brand that is promoted. It is not clear how 
pharmaceutical companies organised themselves to share the responsibilities of brand 
management of products and the corporate image. It is highly likely that companies have 
not even considered it yet. Further research should be carried out to look at how brand 
managers integrate the corporate image into their daily routines. 
 
References were made specifically to pharmaceutical companies and the products 
considered were classed as POMs. The author would argue that there are many 
similarities to those companies producing medical devices, nutriceuticals (foods for special 
medical purposes), veterinary, dental and even cosmetic surgery. There are also 
synergies with over the counter (OTC) products. As such, the concept of segmentation 
described above can easily be adapted to cover these sectors. 
 
Finally, the process of segmentation is confusing; it is compounded by the complicated 
market dynamics of the medical industry. There are a number of bodies (including the 
Chartered Institute of Marketing and the American Marketing Association) that could 
produce clear guidelines on how the industry should organise itself. 
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